To put things into perspective, just 30 years ago, only 25% of adults were overweight.[1] At this rate, experts predict that one billion people will be obese by 2030.[2] This is a burden that simply cannot be sustained on a global healthcare level
doi:10.1556/OH.2012.29370 Lee HJ, Li CW, Hammerstad SS, Stefan M, Tomer Y
This dual approach is a key factor in why tirzepatide might be a particularly effective treatment option for some individuals
Although the FAERS database aids in detecting rare adverse events via spontaneous reporting, its propensity to overestimate unexpected adverse events linked to new therapies makes it inappropriate for comparative analysis of adverse event frequencies among pharmaceuticals
Injections are typically administered subcutaneously
Retrieved 28 January 2013